{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Median duration of response among the responders will be reported along with 95% confidence intervals.","groups":[{"description":"Participants received pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Pembrolizumab)"}],"populationDescription":"Data not collected","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Median Duration of Response (DOR)","type":"SECONDARY"}